Axogen heads into its third-quarter report with a problem most medical device companies would envy and investors still distrust: demand is running ahead of plan, but the wrong kind of demand is eating into profitability. Last quarter management raised its revenue outlook for the third straight time while cutting its gross margin forecast, and the stock has spent the months since sliding toward the bottom of its post-earnings range. The October 28 release, due before the open, will show which half of that story the market should believe.

The Street is looking for revenue of about $72.8 million, up roughly 21% from a year ago, and a loss of three cents a share, compared with a penny of profit in the year-ago quarter. That revenue figure implies continued strong growth, but also a third consecutive quarter of modest deceleration, following 26.6% in the first quarter and 23.1% in the second. The more striking detail is that full-year consensus of about $271 million sits below management's own floor of at least $279 million, a target that implies growth of at least 24%. Either analysts have been slow to update or they doubt the second half. A quarter that lands comfortably above $72.8 million would go a long way toward closing that gap, while a print near consensus could leave investors wondering how much the fourth quarter must carry.

Breast reconstruction is the engine to watch. Management began breaking out the business last quarter after first-half breast revenue grew 47% and supplied about two-thirds of second-quarter growth, with active programs near 215 and surgeons around 560. Continued expansion in those counts would validate the thesis that this is a durable adoption curve rather than a burst of early enthusiasm. The sales force also jumped to 172 reps from 146, and management said new hires were ramping faster than expected. If that held, it should show up as broader growth across the core extremity business, not just breast.

The catch is margin. Breast procedures lean on long-length Avance grafts that cost more to make, and the company's pricing does not scale proportionally with length. Gross margin fell to 72.7% in the second quarter from 75.2% in the first, and guidance now calls for at least 73% for the year, down from 74% to 76%. Management said corrective pricing and efficiency steps will not help until next year, so the realistic hope is stabilization around the new floor. Another step down would suggest mix pressure is outrunning the revised plan, and with adjusted EBITDA margin already down to about 12% from 16% a year earlier, operating expenses growing faster than sales would make the loss estimate look less benign.

The call also carries catalysts. Management promised a detailed prostate update covering more than 100 patients, about half with at least six months of follow-up, and the market will judge whether early positive trends hold up as genuine evidence of a new indication. Any word on Aetna, whose coverage decision slipped past its expected June timing, matters too, since approval could lift commercial coverage from roughly 86% of lives toward the mid-90s.

Sentiment has warmed noticeably, moving from solidly bearish before the last report to roughly neutral now, yet the stock is down 8% since then, trailing the S&P 500 by nearly 12 points. At $35.24 it sits below its 200-day average near $39 and just above the post-earnings low of $34.11, far from the $52.91 peak. That leaves room for relief if Axogen proves the margin reset was a one-time adjustment rather than a trend. The verdict likely rests on whether breast-driven growth keeps the company on track for $279 million without pushing gross margin below 73%.